Terazosinum [Inn-Latin] en es it fr

Terazosinum [Inn-Latin] Brand names, Terazosinum [Inn-Latin] Analogs

Terazosinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Terazosinum [Inn-Latin] Chemical_Formula


Terazosinum [Inn-Latin] RX_link


Terazosinum [Inn-Latin] fda sheet

Terazosinum_[Inn-Latin] FDA

Terazosinum [Inn-Latin] msds (material safety sheet)

Terazosinum [Inn-Latin] Synthesis Reference

M. Winn et al., U.S. Pat. 4,026,894 (1977)

Terazosinum [Inn-Latin] Molecular Weight

387.433 g/mol

Terazosinum [Inn-Latin] Melting Point

273 oC

Terazosinum [Inn-Latin] H2O Solubility


Terazosinum [Inn-Latin] State


Terazosinum [Inn-Latin] LogP


Terazosinum [Inn-Latin] Dosage Forms


Terazosinum [Inn-Latin] Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Terazosinum [Inn-Latin] Pharmacology

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.

Terazosinum [Inn-Latin] Absorption

Essentially completely absorbed in man (90% bioavailability).

Terazosinum [Inn-Latin] side effects and Toxicity

LD50=259.3mg/kg (i.v. in mice)

Terazosinum [Inn-Latin] Patient Information

Terazosinum [Inn-Latin] Organisms Affected

Humans and other mammals